NUCLEOLIN and neuroblastoma: Together with the validation of cell surface NCL expression on Schwannian stroma-poor NB tumors and on bone marrow-infiltrating NB cells, this leads to hypothesize a plausible use of this “targeted nanodrug” in patients suffering from NB.